Fig. 7
From: Caspase-11 signaling enhances graft-versus-host disease
Caspase-11 deficiency preserves graft-versus-leukemia (GVL) activity. a Survival of Casp11+/+ (n = 12) and Casp11−/− (n = 11) recipients had received lethally irradiation (1100 cGy) and transplanted with 5 × 106 BALB/c T cell-depleted bone marrow (TCD-BM) cells alone or in addition to 3 × 106 total T cells from BALB/c mice with 3 × 105 EL4 luciferase-transduced lymphoma cells at the time BM transplant (BMT) was shown. Differences in animal survival were analyzed by log-rank test. **P = 0.0039 (Casp11−/− compared with vehicle-treated controls). b Casp11+/+ (n = 12) and Casp11−/− (n = 11) recipients were monitored throughout the experimental period for weight change by every 3 to 5 days. c Tumor expansion in Casp11+/+ and Casp11−/− recipients was shown by luciferin intraperitoneal injection and whole-body bioluminescent imaging (BLI) was taken every 14 days
